ATE263188T1 - Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate - Google Patents

Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate

Info

Publication number
ATE263188T1
ATE263188T1 AT00935482T AT00935482T ATE263188T1 AT E263188 T1 ATE263188 T1 AT E263188T1 AT 00935482 T AT00935482 T AT 00935482T AT 00935482 T AT00935482 T AT 00935482T AT E263188 T1 ATE263188 T1 AT E263188T1
Authority
AT
Austria
Prior art keywords
synthetic
monoclonal antibodies
biotechnological derivatives
ngf antagonists
ngf
Prior art date
Application number
AT00935482T
Other languages
English (en)
Inventor
Michal M Novak
Original Assignee
Lay Line Genomics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE263188(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lay Line Genomics Spa filed Critical Lay Line Genomics Spa
Application granted granted Critical
Publication of ATE263188T1 publication Critical patent/ATE263188T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00935482T 1999-05-26 2000-05-26 Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate ATE263188T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000333A IT1306704B1 (it) 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
PCT/IT2000/000218 WO2000073344A2 (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules

Publications (1)

Publication Number Publication Date
ATE263188T1 true ATE263188T1 (de) 2004-04-15

Family

ID=11406787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935482T ATE263188T1 (de) 1999-05-26 2000-05-26 Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate

Country Status (12)

Country Link
US (2) US7601352B1 (de)
EP (1) EP1181318B2 (de)
JP (2) JP4917226B2 (de)
AT (1) ATE263188T1 (de)
AU (1) AU776457B2 (de)
CA (1) CA2373274C (de)
DE (1) DE60009484T3 (de)
DK (1) DK1181318T4 (de)
ES (1) ES2218163T5 (de)
IT (1) IT1306704B1 (de)
PT (1) PT1181318E (de)
WO (1) WO2000073344A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
EP2340849A1 (de) * 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF Antikörper zur Behandlung verschiedener Beschwerden
AU2002364257A1 (en) * 2001-12-31 2003-07-24 Sucha Sudarsanam Remote homologues and kinases and methods of detection
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
EP1556083B1 (de) 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2270048B1 (de) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP2298345A3 (de) 2005-01-24 2012-03-21 MedImmune Limited Spezifische Bindungselemente für NGF
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AU2009211340B2 (en) * 2008-02-04 2013-09-12 Lay Line Genomics S.P.A. Anti-TrkA antibodies and derivatives thereof
CN106336400A (zh) 2008-12-08 2017-01-18 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂
KR20120088550A (ko) 2009-05-04 2012-08-08 애보트 리서치 비.브이. 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
SG11201408037SA (en) 2012-06-08 2015-01-29 Glenmark Pharmaceuticals Sa Humanized anti-trka antibodies with amino acid substitutions
EP2674439B1 (de) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Ant-TrkA-Antikörper, Derivate und Verwendungen damit
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015120136A1 (en) 2014-02-05 2015-08-13 VM Oncology LLC Compositions of compounds and uses thereof
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
AR114110A1 (es) * 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
AR122141A1 (es) 2020-05-28 2022-08-17 Lilly Co Eli Inhibidor de trka
JP2025503539A (ja) * 2021-12-28 2025-02-04 ４ビー テクノロジーズ（スーヂョウ） リミテッド ＴｒｋＡ抗体とその応用
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score
AU2024238259A1 (en) 2023-03-17 2025-08-21 Regeneron Pharmaceuticals, Inc. Proteomic risk score for osteoarthritis (oa)
WO2026054762A1 (en) 2024-09-05 2026-03-12 Regeneron Pharmaceuticals, Inc. Proteomic risk score for adjudicated arthropathy (aa)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009225A1 (en) * 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0471205A1 (de) 1990-08-15 1992-02-19 E.R. SQUIBB & SONS, INC. Monoklonale Antikörper, die an TRK Proto-Onkogenproteinen binden
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0598998B1 (de) * 1992-09-07 2004-05-19 Kyowa Hakko Kogyo Co., Ltd Humanisierte Antikörper, die mit dem GM2-Gangliosid reagieren
DK1975181T3 (da) * 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
AU690474B2 (en) * 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU2009211340B2 (en) 2008-02-04 2013-09-12 Lay Line Genomics S.P.A. Anti-TrkA antibodies and derivatives thereof

Also Published As

Publication number Publication date
EP1181318A2 (de) 2002-02-27
JP2003502029A (ja) 2003-01-21
WO2000073344A2 (en) 2000-12-07
JP2012040007A (ja) 2012-03-01
DE60009484D1 (de) 2004-05-06
US8486401B2 (en) 2013-07-16
CA2373274C (en) 2012-08-14
AU776457B2 (en) 2004-09-09
ITRM990333A1 (it) 2000-11-26
EP1181318B2 (de) 2012-03-28
ITRM990333A0 (it) 1999-05-26
IT1306704B1 (it) 2001-10-02
JP4917226B2 (ja) 2012-04-18
CA2373274A1 (en) 2000-12-07
WO2000073344A9 (en) 2002-03-07
WO2000073344A3 (en) 2001-06-28
ES2218163T3 (es) 2004-11-16
DE60009484T3 (de) 2012-06-14
US7601352B1 (en) 2009-10-13
DE60009484T2 (de) 2005-03-24
DK1181318T3 (da) 2004-07-12
PT1181318E (pt) 2004-08-31
ES2218163T5 (es) 2012-06-06
DK1181318T4 (da) 2012-05-29
EP1181318B1 (de) 2004-03-31
US20110206682A1 (en) 2011-08-25
AU5101900A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
DE60009484D1 (de) Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate
NO20025354D0 (no) Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmÕter
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
AU2001294541A1 (en) Mammalian genes; related reagents and methods
ZA200604026B (en) IL-23 and its receptor ; related reagents and methods
DE69714654D1 (de) Verwendung von einem Metalloporphyrinkonjugat für den Nachweis biologischer Verbindungen
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
EP1433792A8 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
WO2001036467A3 (en) Mammalian receptor proteins; related reagents and methods
EP2292760A3 (de) Säuger Zytokine, Receptoren, verwandte Reagentien und Methoden
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
DE60045637D1 (de) Nicotin-acetylcholin rezeptoruntereinheit, deren isolierung und verwendung
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181318

Country of ref document: EP